Poor stem cell harvest may not always be related to poor mobilization: lessons gained from a mobilization study in patients with β-thalassemia major

Transfusion

Volumn 57, Issue 4, 2017, Pages 1031-1039

  Constantinou, Varnavas C ^a,b   Bouinta, Asimina ^b   Karponi, Garyfalia ^a   Zervou, Fani ^a   Papayanni, Penelope Georgia ^a   Stamatoyannopoulos, George ^c   Anagnostopoulos, Achilles ^a,b   Yannaki, Evangelia ^a,b,c  

^a Gene and Cell Therapy Center   (Greece)

^b G PAPANICOLAOU HOSPITAL   (Greece)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; PLERIXAFOR; HETEROCYCLIC COMPOUND;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; LEUKAPHERESIS; MALE; POST HOC ANALYSIS; RETICULOCYTOSIS; SPLENECTOMY; STANDARD; STEM CELL; STEM CELL MOBILIZATION; STEM CELL TRANSPLANTATION; THALASSEMIA MAJOR; BETA-THALASSEMIA; BLOOD; CLINICAL TRIAL; FEMALE; GENE THERAPY; GENETICS; HEMATOPOIETIC STEM CELL;

ADULT; BETA-THALASSEMIA; FEMALE; GENETIC THERAPY; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELLS; HETEROCYCLIC COMPOUNDS; HUMANS; LEUKAPHERESIS; MALE;

EID: 85006998996     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.13951     Document Type: Article

References (23)

1. Cutler C, Antin JH. Peripheral blood stem cells for allogeneic transplantation: a review. Stem Cells 2001;19:108–17.
2. To LB, Haylock DN, Simmons PJ, et al. The biology and clinical uses of blood stem cells. Blood 1997;89:2233–58.
3. Hollingsworth KL, Zimmerman TM, Karrison T, et al. The CD34+ cell concentration in peripheral blood predicts CD34+ cell yield in the leukapheresis product. Cytotherapy 1999;1:141–6.
4. Armitage S, Hargreaves R, Samson D, et al. CD34 counts to predict the adequate collection of peripheral blood progenitor cells. Bone Marrow Transplant 1997;20:587–91.
5. Yang SH, Wang TF, Tsai HH, et al. Preharvest hematopoietic progenitor cell counts predict CD34+ cell yields in granulocyte-colony-stimulating factor-mobilized peripheral blood stem cell harvest in healthy donors. Transfusion 2010;50:1088–95.
6. Tricot G, Jagannath S, Vesole D, et al. Peripheral blood stem cell transplants for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients. Blood 1995;85:588–96.
7. Abrahamsen JF, Wentzel-Larsen T, Bruserud O. Autologous transplantation: the viable transplanted CD34+ cell dose measured post-thaw does not predict engraftment kinetics better than the total CD34+ cell dose measured pre-freeze in patients that receive more than 2 ×10(6) CD34+ cells/kg. Cytotherapy 2004;6:356–62.
8. Yannaki E, Emery DW, Stamatoyannopoulos G. Gene therapy for β-thalassaemia: the continuing challenge. Expert Rev Mol Med 2010;12:e31.
9. Mansilla-Soto J, Riviere I, Boulad F, et al. Cell and gene therapy for the beta-thalassemias: advances and prospects. Hum Gene Ther 2016;27:295–304.
10. Psatha N, Karponi G, Yannaki E. Optimizing autologous cell grafts to improve stem cell gene therapy. Exp Hematol 2016;44:528-39.
11. Yannaki E, Papayannopoulou T, Jonlin E, et al. Hematopoietic stem cell mobilization for gene therapy of adult patients with severe β-thalassemia: results of clinical trials using G-CSF or Plerixafor in splenectomized and nonsplenectomized subjects. Mol Ther 2012;20:230–8.
12. Yannaki E, Karponi G, Zervou F, et al. Hematopoietic stem cell mobilization for gene therapy: superior mobilization by the combination of granulocyte-colony stimulating factor plus Plerixafor in patients with β-thalassemia major. Hum Gene Ther 2013;24:852–60.
13. Karponi G, Psatha N, Lederer CW, et al. Plerixafor + G-CSF-mobilized CD34+ cells represent an optimal graft source for thalassemia gene therapy. Blood 2015;126:616–9.
14. Gambell P, Herbert K, Dickinson M, et al. Peripheral blood CD34+ cell enumeration as a predictor of apheresis yield: an analysis of more than 1,000 collections. Biol Blood Marrow Transplant 2012;18:763–72.
15. Wang TF, Chen SH, Yang SH, et al. Poor harvest of peripheral blood stem cell in donors with microcytic red blood cells. Transfusion 2013;53:91–5.
16. Sanford K, Roseff SD, Anderson J, et al. Harvesting autologous stem cells from a patient with red blood cell abnormalities of β-thalassemia intermedia. Transfusion 2014;54:1881–6.
17. Robertson DA, Simpson FG, Losowsky MS. Blood viscosity after splenectomy. Br Med J (Clin Res Ed) 1981;283:573–5.
18. Tillmann W, Schröter W. Rheological properties of erythrocytes in heterozygous and homozygous beta thalassaemia. Br J Haematol 1979;43:401–11.
19. Sutherland DR, Anderson L, Keeney M, et al. The ISHAGE guidelines for CD34+ cell determination by flow cytometry. International Society of Hematotherapy and Graft Engineering. J Hematother 1996;5:213–26.
20. Vasu S, Leitman SF, Tisdale JF, et al. Donor demographic and laboratory predictors of allogeneic peripheral blood stem cell mobilization in an ethnically diverse population. Blood 2008;112:2092–100.
21. Juneja S, Januszewicz E, Wolf M, et al. Post-splenectomy lymphocytosis. Clin Lab Haematol 1995;17:335–7.
22. Lorber M. The effects of splenectomy on the red blood cells of the dog with particular emphasis on the reticulocyte response. Blood 1958;13:972–85.
23. De Haan LD, Werre JM, Ruben AM, et al. Reticulocyte crisis after splenectomy: evidence for delayed red cell maturation? Eur J Haematol 1988;41:74–9.